A Clinical and Biological Database Study of Lung Cancer Patients Receiving Standard Treatments

What this Trial Is About

Researchers are establishing a clinico-biological database for lung cancer by collecting biological samples and clinical data from patients. This observational study focuses on identifying biological, clinical, and tumor factors linked to tumor response to standard of care treatments. The study includes patients newly diagnosed with lung cancer or suspected lung tumors where antineoplastic treatment is planned. Participants provide blood samples, optional tumor tissue biopsies, and fecal samples at several points before treatment starts, at the first tumor assessment, and at the first and second disease progressions. Genetic analysis is conducted on tumor or healthy tissue and blood to assess constitutional and somatic alterations. All treatments are given as part of standard care without experimental interventions. Throughout the study, clinical data are collected concurrently with sample collection to monitor disease progression and treatment response. The main outcome measured is the tumor response rate evaluated by CT scan after 8 weeks. Secondary outcomes include disease progression rate, progression-free survival, overall survival over one year, and treatment toxicity. Participants are followed over time with repeated assessments and sample collections to support the research objectives.

A Clinico-biological Database of Lung Cancers